News
Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
Hot topic

REGULATION
Law & Regulation
CDE Guideline
Marketing Approval
Priority Review and Approval
NRDL
Health Insurance
Rare Disease
Drug Registration
Real World Data
The 16th Rare Disease Day: China's Efforts to Make Orphan Drugs Available and Affordable
This year’s Feb. 28 marks the 16th International Rare Disease Day. In China, there are around 20 million rare disease patients, with more than 200,000 additional patients each year. China has shown a supportive attitude towards rare disease drug development in a series of official documents. The regulations and policies introduced in this article are significant in terms of the drugs’ marketing authorization review timeline and pricing.
Mar 10, 2023

REGULATION
Law & Regulation
CDE Guideline
Pharmacopoeia
Reference Listed Drug (RLD)
GMP
Clinical Trial
NRDL
Health Insurance
Generic Drug
OTC Drug
Cancer
Monthly Recap: China Pharmaceutical Regulatory Updates | September 2022
Find out the latest pharmaceutical regulatory updates in China: 1. China SAMR to Permit Online Sales of Prescription Drugs Nationwide; 2. China NMPA Grants One Rx-to-OTC Switch; 3. China NMPA Releases 183 RLDs; 4. China CFDI Consults on Inspection Guidance for Blood Products; 5. China NHSA Announces 343 Drugs Passing the Format Review for NRDL; 6. China CDE Releases Pharmaceutical Guidelines; 7. Chinese Pharmacopoeia Commission Consults on Drafts of Drug Standards and Guideline
Oct 03, 2022

REGULATION
Law & Regulation
MAH
Pharmacovigilance
Marketing Approval
Priority Review and Approval
Health Insurance
Innovative Drug
Generic Drug
Rare Disease
Drug Registration
New Drug
China Encourages Innovative Drug R&D in Revised Draft of Regulations for Implementing the Drug Administration Law
Find out the highlights in revised draft of the Regulations for Implementation of the Drug Administration Law: pharmaceutical innovation, acceptance of foreign clinical data, support the development of pediatric and rare disease drugs...
May 13, 2022

POLICY
Law & Regulation
Marketing Approval
Volume-based Procurement
Health Insurance
Innovative Drug
Cancer
Cardiovascular Disease
Rare Disease
Drug Registration
New Drug
China's 2022 Two Sessions: Goals and Proposals for Pharma & Healthcare Industry
China's Government Work Report says one off the major tasks for 2022 is to improve medical and health services.
Mar 15, 2022

INDUSTRY
Best-selling Ophthalmic Drugs in China | Market Wrap 2021
The year 2021 has seen a remarkable growth of the ophthalmic drug market in China. The market size of chemical drugs for eye diseases is estimated to exceed 3.5 billion yuan (circa 549 million USD), with a year-on-year growth of 1.89%.
Jan 10, 2022

POLICY
China Adds 74 Drugs to National Reimbursement Drug List (NRDL)
On Dec. 3, China released its 2021 National Reimbursement Drug List (NRDL). NRDL is a list of drugs allowable for reimbursement by the national social health insurance fund under the social security system which has covered more than 1.36 billion people in China by the end of 2020.
Dec 08, 2021

POLICY
China Promotes Distribution of Medicare-covered Drugs Through Dual Channel
China permits qualified drug stores to sell prescription drugs included in the National Reimbursement Drug List. At these drug stores, people can enjoy the same medical care payment coverage with hospitals. The policy intends to add another sales channel for the drugs outside hospitals, especially for the newly listed drugs through centralized procurement.
May 24, 2021

INDUSTRY
In Light of the 14th Rare Disease Day, How Is China Doing on Rare Disease Drugs?
On February 28, 2021, the international community observes the 14th Rare Disease Day, which is a time of the year to raise awareness among the general public and to also reflect upon the progress of orphan drugs development.
Mar 08, 2021
Most Popular
- [Updated] China Issues the 2020 Edition of Chinese Pharmacopoeia
- Monthly Report: New Drug Approvals in China | March 2023
- What's New About China's 8th Volume-based Procurement (VBP) of Drugs
- Monthly Recap: China Pharmaceutical Regulatory Updates | March 2023
- For Injectable Complex Generics, China Has Special CMC Requirements



